Evidence map›Paper›PMID 33329541›Full record

ArticleFrontiers in immunology2020

Very Early Involvement of Innate Immunity in Peripheral Nerve Degeneration in SOD1-G93A Mice.

Daniela Francesca Angelini, Federica De Angelis, Valentina Vacca, Eleonora Piras, Chiara Parisi, Michele Nutini, Alida Spalloni, Francesca Pagano, Patrizia Longone, Luca Battistini and 2 more

Erratum issuedOpen access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Inhibition of glycolytic reprogramming suppresses innate immune-mediated inflammation in experimental amyotrophic lateral sclerosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Daniela Francesca AngeliniNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Federica De AngelisNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Valentina VaccaCNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.
Eleonora PirasNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Chiara ParisiCNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.
Michele NutiniNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Alida SpalloniNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Francesca PaganoCNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.
Patrizia LongoneNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Luca BattistiniNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Flaminia PavoneCNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.
Sara MarinelliCNR-National Research Council, Institute of Biochemistry and Cell Biology, Rome, Italy.
Fondazione Santa Lucia · ITInstitute of Cell Biology and Neurobiology · ITNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent preclinical and clinical evidence suggest that immune system has a role in the progression and prognosis of Amyotrophic Lateral Sclerosis (ALS), but the identification of a clear mechanism and immune players remains to be elucidated. Here, we have investigated, in 30 and 60 days (presymptomatic) and 120 days (symptomatic) old SOD1-G93A mice, systemic, peripheral, and central innate and adaptive immune and inflammatory response, correlating it with the progression of the neurodegeneration in neuromuscular junction, sciatic nerves, and spinal cord. Surprisingly, we found a very initial (45-60 days) presence of IgG in sciatic nerves together with a gradual enhancement of A20/TNFAIP3 (protein controlling NF-κB signalling) and a concomitantly significant increase and activation of circulating mast cells (MCs) as well as MCs and macrophages in sciatic nerve and an enhancement of IL-6 and IL-10. This immunological frame coincided with a myelin aggregation. The 30-60 days old SOD1-G93A mice didn't show real elements of neuroinflammation and neurodegeneration in spinal cord. In 120 days old mice macrophages and monocytes are widely diffused in sciatic nerves, peripheral neurodegeneration reaches the tip, high circulating levels of TNFα and IL-2 were found and spinal cord exhibits clear signs of neural damage and infiltrating immune cells. Our results underpin a clear immunological disorder at the origin of ALS axonopathy, in which MCs are involved in the initiation and sustaining of inflammatory events. These data cannot be considered a mere epiphenomenon of motor neuron degeneration and reveal new potential selective immune targets in ALS therapy.

Indexed as

Amyotrophic Lateral SclerosisImmunity, InnateNeuroimmunomodulationNeuromuscular JunctionSciatic NerveSpinal CordSuperoxide Dismutase-1Wallerian DegenerationAnimalsDisease Models, AnimalDisease ProgressionGenetic Predisposition to DiseaseInterleukin-10Interleukin-6MacrophagesMaleIL10 protein, mouseInterleukin-10Interleukin-6interleukin-6, mouseNF-kappa BSOD1 protein, humanSuperoxide Dismutase-1amyotrophic lateral sclerosisautoimmunitydemyelinationmast cellsmonocytes/macrophagesperipheral nerve degenerationpro-inflammatory cytokineWallerian-like degeneration

Identifiers

PMID33329541
PMCPMC7714949
OpenAlexW3109303139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.